Figure 6. TG101209 impairs AE9a leukemia-initiating activity.

(A) Percentages of EGFP+ cells in peripheral blood of MF-1 mice receiving 1 × 10⁴ sorted EGFP+ spleen cells from primary transplanted AE9a leukemia mice that had been treated with placebo or TG101209 (100 mg/kg) once daily for two weeks. Peripheral blood was examined at 6 and 12 weeks after secondary transplantation. At 12 weeks, there were only 5 live mice left in the placebo group (n = 8) and all of them had > 50% EGFP+ cells in blood. (B) Survival curves showing the lifespan of the secondary transplanted MF-1 mice in (A). *The remaining five mice in the TG101209 group (n = 8) had no detectable EGFP+ cells at the end point of the study and appeared healthy. The p values were determined by Student’s t-test (A) or Log-rank test (B). The results from one of two independent experiments are shown.